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Editorial on the Research Topic
Updates on Osteoimmunology: What’s New on the Crosstalk Between Bone and Immune Cells
Osteoimmunology is an important field of bone research, it deepens the crosstalk between bone,
and immune cells in both physiological and pathological conditions (1). The relative mechanisms
were reported in the papers of this special issue, grouped into different categories: general
mechanisms, pathological conditions, and potential therapeutics.
OSTEOIMMUNOLOGY GENERAL MECHANISMS
Ponzetti and Rucci reviewed in detail this topic. They reported that many cytokines that are
considered immune-related, such as Interleukins, Tumor Necrosis Factor (TNF)-α, and Receptor-
Activator of Nuclear factor Kappa B Ligand (RANKL), have all been demonstrated to be critical
in osteoblast and osteoclast biology. On the other hand, bone cells, crucial for bone remodeling,
actually regulate immune cells, and thus the endosteal niche. Both osteoclasts and osteoblasts
take part to this niche, either by supporting engraftment, or mobilization of Hematopoietic Stem
Cells (HSCs).
Interestingly, Lombardi et al. explored the effect of physical activity on bone metabolism, taking
into account not only the direct role of biomechanical load, but also focusing on the role of
immunomodulation. Although the majority of the studies point to the inflammation-mediated
effects of physical activity, it has been shown that it regulates immune function through the
inflammasomes, and through the secretion of myokines and adipokines. Although it is known that
regular physical activity is effective in improving and maintaining bone mass, there is no consensus
on the best kind of exercise to prescribe.
Additionally, Xiao and Xiao described autophagy involvement in osteoimmunology.
Autophagy is a cytologic essential event for dysfunctional organelles degradation thus
involved in cell survival; the process is also responsible for immune cell polarization (2).
Bone cells use autophagy for their main functions, in particular osteoclast differentiation,
polarization and adhesion to bone matrix depend on autophagy (3); osteoblasts through their
phagosomes secrete calcium phosphate crystals in extracellular matrix supporting osteoid matrix
mineralization (4). Differently, autophagy inhibits osteocytes oxidative stress consequences,
neutralizing damaged mitochondria that could induce apoptosis (5). The authors concluded
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that autophagy, driving the inflammatory process in the immune
cells, have important consequences on bone tissue not only in
physiological remodeling but also in the diseases.
Interestingly, Fischer et al. revised the role of Foxp3+
regulatory T cells, a particular subset of CD4+ T cells, in bone
and hematopoietic homeostasis (6, 7). Foxp3+ Treg cells play
a crucial role in preserving immune homeostasis, but may also
control regenerative and metabolic processes, osteoclast activity,
and differentiation of HSCs. Foxp3+ Treg cells affect lympho-
haematopoiesis through indirect mechanisms, i.e., by acting on
osteoclast differentiation and activity, which determines changes
in the niche size.
In the review by Metzger and Narayanan the authors
synthetized the role of osteocytes in immune mediated
bone pathological events (8). Aging, changes the canalicular
communication between osteocytes impairing their
communication features, moreover, in old mice, osteocytes
increase the production of inflammatory cytokines,
increasing bone resorption. Pro-inflammatory signals can
directly determine osteocytes apoptosis affecting bone
turnover, or can stimulate osteocytes in the production of
anti-osteoblastic or pro-osteoclastic cytokines stimulating
bone loss.
OSTEOIMMUNOLOGY AND
PATHOLOGICAL CONDITIONS
Osteoimmunology key mechanisms have been also highlighted
in different pathological conditions (9–12), and in this special
issue on obesity, osteopetrosis, osteolytic solid tumors, and
multiple myeloma.
Childhood obesity is one of the main health problems
worldwide. The excess of adipose tissue leads to inflammation,
oxidative stress, apoptosis, and endothelial dysfunctions (13).
Severe comorbidities are associated with obesity, most of them
developing already in childhood (14). Among these, low bone
mineral density, osteoporosis, and fracture risk have been
observed in subjects with various degree of obesity. Faienza
et al., reviewed the mechanisms involved in obesity-related bone
fragility. The authors reported that the accumulation of adipose
tissue positively regulates the function of osteoclasts, the bone
reabsorbing cells, by up-regulating the production of several
cytokines as RANKL, LIGHT, TRAIL, TNFα, and Monocyte
Chemotactic Protein-1 (MCP1). In addition, in obese subjects the
osteoblastogenesis is inhibited, thereby the result is an enhanced
bone resorption.
Osteopetrosis is a rare bone disease characterized by increased
bone mass due to defects in osteoclast function or formation
(15). Penna et al. deal with this interesting topic reviewing
the clinical and genetic heterogeneity of the disease and
underscoring the importance of the research in order to develop
further innovative treatment for this rare and often lethal
disease. Treatment of these patients if often limited by the
presence of neurodegeneration, however hematopoietic stem cell
transplantation can be successfully applied in several patients,
this treatment is effective only during the first months of life,
hence a precocious molecular diagnosis is fundamental.
The research article of Zhang et al. reported an analysis on
the single-nucleotide polymorphisms (SNPs) and expression of
NLRP3 inflammasome related genes, NF-κB, NLRP3, IL-1β, IL-
18, Caspase-1, and ASC in 308 acute lymphoblastic leukemia
(ALL) patients and 300 healthy controls. Inflammasomes are
large cytosolic multiprotein complexes that activate the caspase-
1-mediated innate immune responses. The results of this
study demonstrated an involvement of NLRP3 inflammasome-
related SNPs, especially NF-κB-94ins/del ATTG and CARD8
(rs2043211) genotype, in ALL. Thus, this genetic variant of
NLRP3 inflammasome could be a new biomarker and potential
targets for ALL. Furthermore, IL-1β (rs16944) and IL-18
(rs1946518) polymorphism seem to predict ALL prognosis.
Notably, ALL patients developed osteonecrosis (16), thus is
fundamental the identification of new markers as well as
therapeutic targets.
Bone is a preferred metastatic site for several cancer and
cancer cells may remain dormant for years within bone before
growing, thanks to their ability to overcome the immune system
(17). Roato and Vitale deal with the interesting and under-
investigated topic of bone metastatic niche, the relation with
immune system and the role of Natural Killer (NK) cells
in the control of bone metastases growth. They suggest that
the stimulation of NK cells activity by the use of cytokine
combinations and blocking of their checkpoint receptors can be
crucial in increasing the opportunity for new therapeutic options
in the treatment of bone metastatic disease.
Harmer et al. highlighted the role of interleukin 6 (IL-
6) in multiple myeloma, a hematological malignancy of the
plasma cells (18). About 80% of patients display the osteolytic
bone disease at diagnosis, and different mechanisms have
been demonstrated to orchestrate the negative process, such
as IL-6 (18). It is an inflammatory cytokine that affects
osteoclast differentiation and plasma cell proliferation. In
multiple myeloma, IL-6 is responsible of bone homing, osteolytic
process, progression as well as drug resistance. The review
also reported current and potential therapeutic approaches
against IL-6.
OSTEOIMMUNOLOGY AND POTENTIAL
THERAPEUTICS
In the research paper by Massaccesi et al. the authors
demonstrated Vitamin E effects on ultrahigh molecular weight
polyethylene (UHMWPE). UHMWPE are currently used for
joint prothesis, they determine the reduction of wear particles
formation with a consequent decrease of free radicals’ generation.
Bone remodeling activity in sites close to UHMWPE prosthetic
devices, can be affected by oxidative stress. Thus, oxidative
stress can induce either osteoclast differentiation or osteoblast
apoptosis leading to bone resorption. Vitamin E, being a
powerful antioxidant molecule, could be proposed in joint
prosthetic devices to decrease prothesis wear and at the same
time inhibit the influences of the oxidation-induced osteolysis
promoting osteoblast survival and osteoblasts apoptosis. The
authors concluded that Vitamin E-Stabilization on UHMWPE
could be used to increase the life of joint prothesis.
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Kishikawa et al. studied the role of Docosahexaenoic acid
(DHA) in inflammation-induced osteoclast formation. DHA,
an n-3 fatty acid, is an important structural component of
the cell membrane, regulates osteoclast differentiation, and
activity and has a potent anti-inflammatory effect through G
protein-coupled receptor 120 (GPR120), a functional receptor
for n-3 fatty acids (19). Kishikawa et al. displayed that both
RANKL- and TNF-α-induced osteoclastogenesis was inhibited
by DHA. The authors also reported that the number of
osteoclasts, bone resorption pits and the level of resorption
marker were significantly lower in LPS+DHA-co-administered
mice than LPS-administered mice. However, this DHA-induced
inhibition was not found in LPS-, DHA-, and selective GPR120
antagonist AH7614-co-administered mice. Thus, the authors
concluded that DHA inhibits LPS-induced osteoclast formation
and activity in vivo via GPR120 by inhibiting LPS-induced TNF-
α secretion by macrophages together with the direct inhibition
of osteoclastogenesis.
Nicolin et al. focused on the current knowledge on the
role of plant-derived polyphenols in suppressing osteoclast
differentiation and bone resorption. Polyphenols are natural
molecules derived from plants isolated and characterized in the
fruits, and vegetables (20). Some of these bioactive compounds
have bone anabolic action, by inhibiting bone resorption.
Probably, polyphenols could affect bone metabolism through
impairment of cytokines which are involved in promoting
osteoclast differentiation and resorption. Furthermore, these
compounds have antioxidant characteristics, since they can act
as scavengers of reactive oxygen species (ROS). However, further
studies are needed on the application of these compounds as
therapeutic alternative to current therapies (21) in bone diseases.
In conclusion, all the articles dispensed an overview of
the mechanisms regulating bone immune cell crosstalk in
physiological and pathological conditions, thus identifying
possible alternative therapeutic targets.
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